title: Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).
abstract: Neoangiogenesis in tumours contributes to the development of blood-borne metastases, and can be evaluated by markers of activated endothelial cells in preference to panendothelial markers. Our purpose was to document the prognostic significance of VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 immunoexpression in breast carcinoma frozen samples (n=905, follow-up=11.7 years). We observed that: (i). CD105 (P=0.001) and Tie-2/Tek (P=0.025) (but not VEGF-R1 and VEGF-R2) overexpression correlated with a shorter survival, and were (Cox's model) independent histoprognostic indicators; (ii). only CD105 marked expression correlated (P=0.035) with a shorter survival of node-negative patients; (iii). three markers - CD105 (P=0.001), Tie-2/Tek (P=0.01), VEGF-R1 (P=0.001), but not VEGF-R2 - correlated with metastatic risk in node-negative patients in univariate analysis; and (iv). VEGF-R1 (P=0.01) expression correlated with high local recurrence risk. It is concluded that CD105 and to a lesser extent Tie-2/Tek and VEGF-R1, but not VEGF-R2 are endowed with prognostic significance that may be useful for patient monitoring, particularly CD105 expression for selecting node-negative patients for more aggressive postsurgery therapy.
authors.affiliation: Department of Pathology, Centre Hospitalier et Universitaire Nord, Marseille Cedex 20, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Dales
authors.forename: S
authors.initials: S
authors.lastname: Garcia
authors.forename: S
authors.initials: S
authors.lastname: Carpentier
authors.forename: L
authors.initials: L
authors.lastname: Andrac
authors.forename: O
authors.initials: O
authors.lastname: Ramuz
authors.forename: M N
authors.initials: MN
authors.lastname: Lavaut
authors.forename: C
authors.initials: C
authors.lastname: Allasia
authors.forename: P
authors.initials: P
authors.lastname: Bonnier
authors.forename: C
authors.initials: C
authors.lastname: Taranger-Charpin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D018572:Disease-Free Survival; D000071063:Endoglin; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D042787:Receptor, TIE-2 / Q000032:analysis* / Q000096:biosynthesis; D011956:Receptors, Cell Surface; D012307:Risk Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis* / Q000096:biosynthesis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis* / Q000096:biosynthesis; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000032:analysis* / Q000096:biosynthesis
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D019010:Vascular Cell Adhesion Molecule-1; D042787:Receptor, TIE-2; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2